BR0303092A - Portfólio para prognóstico de câncer de mama - Google Patents

Portfólio para prognóstico de câncer de mama

Info

Publication number
BR0303092A
BR0303092A BR0303092-0A BR0303092A BR0303092A BR 0303092 A BR0303092 A BR 0303092A BR 0303092 A BR0303092 A BR 0303092A BR 0303092 A BR0303092 A BR 0303092A
Authority
BR
Brazil
Prior art keywords
breast cancer
portfolio
cancer prognosis
genes
gene
Prior art date
Application number
BR0303092-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Yixin Wang
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29215884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0303092(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BR0303092A publication Critical patent/BR0303092A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR0303092-0A 2002-03-29 2003-03-28 Portfólio para prognóstico de câncer de mama BR0303092A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36878902P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
BR0303092A true BR0303092A (pt) 2004-09-08

Family

ID=29215884

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0303092-0A BR0303092A (pt) 2002-03-29 2003-03-28 Portfólio para prognóstico de câncer de mama

Country Status (11)

Country Link
US (1) US7473526B2 (cg-RX-API-DMAC7.html)
EP (1) EP1367138B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003325192A (cg-RX-API-DMAC7.html)
KR (1) KR20030078805A (cg-RX-API-DMAC7.html)
CN (1) CN1495274A (cg-RX-API-DMAC7.html)
AR (1) AR039213A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003203557B2 (cg-RX-API-DMAC7.html)
BR (1) BR0303092A (cg-RX-API-DMAC7.html)
CA (1) CA2422303A1 (cg-RX-API-DMAC7.html)
DE (1) DE60317606T2 (cg-RX-API-DMAC7.html)
MX (1) MXPA03002864A (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
WO2005083429A2 (en) * 2004-02-20 2005-09-09 Veridex, Llc Breast cancer prognostics
JP2007532142A (ja) * 2004-04-23 2007-11-15 エグザジェン ダイアグノスティクス インコーポレイテッド 乳がん遺伝子発現バイオマーカー
US20070130694A1 (en) * 2005-12-12 2007-06-14 Michaels Emily W Textile surface modification composition
EP1983046A4 (en) * 2006-02-03 2009-03-25 Messengerscape Co Ltd GENERAL GROUP APPLICABLE TO CANCER PROSTICE
WO2008073578A2 (en) 2006-12-08 2008-06-19 Iowa State University Research Foundation, Inc. Plant genes involved in nitrate uptake and metabolism
EP2321789B1 (en) * 2008-07-01 2017-09-06 The Board of Trustees of The Leland Stanford Junior University Methods for assessment of clinical infertility
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
GB0821787D0 (en) * 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
US8790916B2 (en) 2009-05-14 2014-07-29 Genestream, Inc. Microfluidic method and system for isolating particles from biological fluid
SG190867A1 (en) 2010-11-23 2013-07-31 Krisani Biosciences P Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US635152A (en) * 1899-06-05 1899-10-17 Melancthon S Shotwell Car-body bolster.
US6350576B1 (en) 1994-12-20 2002-02-26 Cold Spring Harbor Laboratory Cancer detection probes
DE69637552D1 (de) 1995-03-17 2008-07-10 Wayne John Cancer Inst Nachweis von Brustmetastasen unter Verwendung eines Mehrfachmarker-Tests
US6275814B1 (en) 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6037129A (en) 1998-05-28 2000-03-14 Medical University Of South Carolina Multi-marker RT-PCR panel for detecting metastatic breast cancer
US6175624B1 (en) * 1999-03-05 2001-01-16 Centurion International, Inc. Method for connecting a battery circuit in a cellular telephone
EP1163524A2 (en) 1999-03-15 2001-12-19 EOS Biotechnology, Inc. Methods of screening for colorectal cancer modulators
JP2004507202A (ja) * 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
US6175824B1 (en) 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators
KR20020092891A (ko) 1999-07-15 2002-12-12 리서치 디벨럽먼트 파운데이션 코르티코트로핀 분비 인자 수용체 2 결핍 마우스 및 이의용도
US20030235533A1 (en) * 2002-02-19 2003-12-25 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
US20050054826A1 (en) * 2003-05-19 2005-03-10 Rosetta Inpharmatics Llc Human diaphanous-3 gene and methods of use therefor

Also Published As

Publication number Publication date
DE60317606D1 (de) 2008-01-03
KR20030078805A (ko) 2003-10-08
AU2003203557B2 (en) 2007-05-24
AU2003203557A1 (en) 2003-10-23
MXPA03002864A (es) 2004-08-11
CA2422303A1 (en) 2003-09-29
CN1495274A (zh) 2004-05-12
US7473526B2 (en) 2009-01-06
EP1367138A2 (en) 2003-12-03
JP2003325192A (ja) 2003-11-18
US20030190656A1 (en) 2003-10-09
AR039213A1 (es) 2005-02-09
DE60317606T2 (de) 2008-10-23
EP1367138A3 (en) 2004-03-10
EP1367138B1 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
BR0303011A (pt) Painel de diagnóstico de câncer
Bryzgunova et al. Isolation and comparative study of cell‐free nucleic acids from human urine
Seuk Kim et al. Aberrant methylation of H‐cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma
Finlay-Schultz et al. New generation breast cancer cell lines developed from patient-derived xenografts
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
Szczepanowski et al. Cell‐of‐origin classification by gene expression and MYC‐rearrangements in diffuse large B‐cell lymphoma of children and adolescents
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO2002079411A3 (en) Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
Salcedo-Hernández et al. Synovial sarcomas of the head and neck: comparative analysis with synovial sarcoma of the extremities
AR043808A1 (es) Pronostico de cancer colorrectal
MXPA03002864A (es) Portafolios de pronostico de cancer de mama.
ATE175996T1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
AR044099A1 (es) Pronostico de cancer de mama
Snow et al. Molecular analysis of NUT‐positive poromas and porocarcinomas identifies novel break points of YAP1:: NUTM1 fusions
Cocciadiferro et al. Profiling cancer stem cells in androgen‐responsive and refractory human prostate tumor cell lines
Coates Markers of senescence?
Anker et al. Progress in the knowledge of circulating nucleic acids: plasma RNA is particle-associated. Can it become a general detection marker for a cancer blood test?
Ayyathurai et al. Prostatic involvement by urothelial carcinoma of the bladder: clinicopathological features and outcome after radical cystectomy
EP1226153A4 (en) FLUORESCENT COBALAMINES AND ITS USE
CY1115258T1 (el) Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων
Bryan et al. Molecular pathways in bladder cancer: part 2
BRPI0608429A2 (pt) método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido
PT1058739E (pt) Metodo para produzir perfis de expressao genica
DE69913533D1 (de) Reagentien für cyp2d fluoreszenztest
IL126257A (en) Immuno-magnetic cell separation for use in identification of genes associated with site-preferenced cancer methastasis formation

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2042 DE 23/02/2010.